Haematopoietic stem cell gene therapy - Novartis/SyStemix

Drug Profile

Haematopoietic stem cell gene therapy - Novartis/SyStemix

Alternative Names: CD34 anti-HIV gene therapy; CD34 anti-HIV therapy; CD34 gene therapy; Haematopoietic stem cell anti-HIV gene therapy; HSC anti-HIV gene therapy; HSC anti-HIV therapy; HSC gene therapy

Latest Information Update: 10 Dec 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Duke University; Novartis; SyStemix
  • Developer SyStemix
  • Class Antivirals; Gene therapies
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 17 Sep 1999 No-Development-Reported for HIV infections treatment in USA (Unknown route)
  • 01 May 1997 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top